Abstract
Introduction
Irreversible electroporation (IRE) is a novel tumour ablation technique based on the local application of an electrical field between two or more electrodes inserted around a tumour.
Multiple cycles of short, extremely high-voltage electrical pulses alter the transmembrane potential of tumour cells, leading to the creation of nanoscale defects in the lipid bilayer of the cell membrane, increasing membrane permeability. With the appropriate electrical parameters (90 pulses of 70 μsec; electric field strength 1500 V/cm; delivered current Ampère), the membrane permeability becomes permanent and the cell eventually dies due to loss of homeostasis (1, 2) . Because cell death in IRE is based on electrical energy rather than thermal energy, the technique has two advantages over thermal ablation techniques like radiofrequency ablation (RFA). Firstly, whilst IRE effectively destroys all cells within the ablation area, the extracellular matrix is preserved. As a consequence, vascular, biliary and nervous structures rich in extracellular collagenous and elastic structures remain intact (3, 4) .
Secondly, IRE is unaffected by the so-called 'heat-sink effect', in which incomplete tumour ablation may occur near large vessels due to loss of heat via blood flow (5) . Therefore, IRE may represent an effective alternative for tumours that cannot be resected or thermally ablated due to unfavourable location. In light of the promising results of the first trials investigating the safety and efficacy of IRE in different organs, we anticipate that the therapeutic use of IRE will expand rapidly in the near future (6) (7) (8) (9) .
For the anaesthesiologist, the pulsatile application of electrical pulses with a very high voltage presents specific challenges, including the possible triggering of cardiac arrhythmias caused by increased cell membrane permeability of electroporated tissue, which opens a path for ion transport (10) . Also, severe muscle contractions and epileptic seizures could occur due to stimulation of muscular or nervous tissue (11) . Therefore, specific precautions in intraprocedural management are required in order to safely perform IRE. For example, as complete muscle paralysis is necessary to prevent muscle contractions, all IRE procedures require general anaesthesia and the use of muscle relaxants. Furthermore, to prevent arrhythmias the electrical pulses must be administered synchronously to the heart rhythm, since external electrical stimuli delivered during the absolute refractory period of the heart are incapable of inducing an action potential (10) .
Current literature on anaesthetic management for IRE procedures is limited to a single publication by Ball and colleagues, who reported their initial experience in 21 patients treated with CT-guided percutaneous IRE for hepatic, renal and pulmonary tumours and formulated guidelines for this procedure (11) . In our study, we aimed to broaden the experience of open and percutaneous IRE to an additional patient population with different tumour types and to confirm previous formulated guidelines for anaesthetic management.
To this end, we specifically focused on IRE-related side-effects and the appropriate precautions with respect to anaesthetic management of open and percutaneous procedures in different organs.
Methods
This study was conducted with the approval of the Medical Ethics Committee of the VU University Medical Center. The study was designed and conducted in accordance with Good Clinical Practice and the principles of the Declaration of Helsinki. All patients provided written informed consent.
Patients
All patients treated with open or percutaneous IRE between August 2012 and September 2013 were prospectively included in a database and analysed. This included patients participating in the COLDFIRE-I trial, in which patients who were already scheduled for surgical resection of colorectal liver metastases (CRLM) were treated with IRE during surgery 60 minutes prior to resection (Clincaltrials.gov registration number: NCT01799044). All other patients underwent IRE in the liver, pancreas, kidney or lesser pelvis on clinical indication, due to proximity of the tumour to vital structures precluding surgical resection or thermal ablation. A designated multidisciplinary board determined local treatment. All patients had a histologically proven malignancy and underwent appropriate preprocedural imaging.
Inclusion criteria were ASA classification ≤3 and adequate bone marrow, hepatic and renal function. Exclusion criteria were cardiac arrhythmias requiring anti-arrhythmic therapy or pacemaker/implantable cardioverter-defibrillator, a history of congestive heart failure (NYHA-class >2), active coronary artery disease, uncontrolled hypertension and epilepsy.
Anaesthetic management
Preoperative screening was performed with specific emphasis on contraindications for IRE.
Patients undergoing laparotomy received a thoracic epidural prior to surgery. The anaesthesia technique used was standardized to avoid bias. Based on personal preferences as well as a practical issue (not all anaesthesia machines in the radiology department of our institution are equipped with proper scavening systems that allow the use of volatile anesthetics), total intravenous anaesthesia was induced with propofol (2 mg kg(0.3 mcg kg -1 ) and rocuronium (0.6 mg kg -1 ) and maintained with propofol and remifentanil.
The Accusync ECG gating device (model 72; Milford, Connecticut) was connected to a 5-lead ECG to allow IRE pulses to be synchronized with the refractory period of the heart to avoid arrhythmias. Two defibrillation pads were placed and connected to a defibrillator as a precautionary measure. Immediately prior to IRE, complete muscle relaxation was confirmed by a train-of-four (TOF)-ratio of 0, using a peripheral nerve stimulator (TOF-Watch ® , MIPM, Mammendorfer, Germany) to assess neuromuscular transmission. When necessary, an additional dose of rocuronium was administered.
After laparotomy, the epidural stayed in situ for at least 3 days. Pain control after percutaneous procedures was managed with acetaminophen combined with an NSAID (diclofenac), and an opioid (piritramide) if needed.
Safety analysis
All adverse events were graded according to the Common Terminology Criteria for Adverse Events (NCI CTCAE v4.0). Cardiac rhythm, blood pressure and saturation were continuously monitored. ECGs were monitored continuously until discharge from the recovery ward, and another 12-lead ECG was made one day post-IRE. Blood samples were evaluated with a special emphasis on serum electrolytes, renal function and hepatic or pancreatic enzymes that could identify biochemical disturbances possibly caused by cellular destruction. These samples were drawn within 7 days prior to IRE, within 5 minutes following IRE and at least one day after the procedure. To monitor brain activity and the effect of pulses on the cerebrum prior to and during IRE, a simplified electroencephalogram (EEG) was made in six patients using the Thymatron System IV (Schwind Benelux Medical Electronics BV, Oosterbeek, The Netherlands). Postprocedural pain was scored three times a day during hospital admission, using the Visual Analogue Scale (VAS).
Intervention
All procedures were performed by a board-certified interventional radiologist trained in IRE.
Before IRE, the size and shape of the target lesion, including a 1cm tumour-free margin, were defined; this determined the number and configuration of the electrodes. Two or more insulated 15cm needle electrodes with an exposure length of 2cm (liver, kidney and lesser pelvis) or 1.5cm (pancreas) were placed in the outer border of the tumour with an interprobe distance of 2.0cm (± 0.2cm). During laparotomy, intraoperative ultrasound (Alpha7, Hitachi Aloka Medical, Ltd. Tokyo, Japan) was used to aid electrode placement. For percutaneous procedures, the electrodes were advanced under CT fluoroscopy (Volume Zoom, Siemens, Erlangen, Germany), with or without ultrasound (figure 1). To allow needle placement under CT fluoroscopy, ventilation was briefly stopped.
After confirmation of correct electrode position, the appropriate parameters for voltage (1500V/cm), number of pulses (90) and pulse interval (70μs) were set, and ablation was started using the NanoKnife, a low-energy direct-current ablation device (AngioDynamics, Latham, NY). The pulses were synchronized with the heart rhythm, as detailed above. The delivered current should lie between 20-50A, and in case of overcurrent (>50A) a safety mechanism automatically turns off energy delivery to prevent thermal injury. If necessary, electrodes were repositioned for renewed ablation until the ablation zone fully covered the tumour.
Statistical analysis
All data were described and analysed; continuous variables were presented as mean and standard deviation (normal distribution), median and range (non-normal distribution), or frequencies and percentages (categorical variables). A p-value <0.05 was considered significant. Analysis was performed using SPSS 20.0 (SPSS Inc, Chicago). 
Results
A total of 28 patients with ASA-classification I (n=4), II (n=23) and III (n=1) were treated with IRE in 30 sessions. Thirteen patients were treated during laparotomy for CRLM, of whom 10 patients participated in the COLDFIRE study. All these patients underwent resection and RFA of additional lesions. The remaining 15 patients were all treated percutaneously for CRLM (n=5), pancreatic carcinoma (n=5), cholangiocarcinoma (n=1), hepatic adenoma (n=1), renal cell carcinoma (n=1) and presacral metastasis of colorectal carcinoma (n=2). Two patients were treated twice due to local recurrence (presacral metastasis and cholangiocarcinoma). Two to six electrodes were used for each procedure, depending on the size of the target lesion. Cardiovascular effects: hypertension and arrhythmias
During electroporation, an elevation of systolic and diastolic blood pressure was observed in most patients, with a median of 44mmHg (range -7-108mmHg) and 19mmHg (range 1-50mmHg) compared to baseline. This was most pronounced during pancreatic IRE (60mmHg and 30mmHg) ( Table 1 ). This elevation was easily managed with additional propofol and remifentanil, and blood pressure returned to baseline within minutes after IRE. Heart rate showed a moderate increase during electroporation (median 10/min, range -7-32), and seemed more profound during IRE of the pancreas (18/min) than of the other organs (8/min), although this difference was not significant (Table 1) .
During two IRE procedures, a minor self-limiting cardiac arrhythmia was observed.
Ventricular extrasystole was observed during open IRE apical in the liver near the left diaphragm. Cardiac rhythm normalized after abortion of the procedure and could be continued after removal of the electrode that was closest to the heart. The second arrhythmia, bigeminy with premature ventricular complex, occurred during pancreatic ablation but disappeared within 5 minutes of the end of the procedure. Neither minor arrhythmia led to haemodynamic instability. All ECGs made one day after IRE were without abnormalities and similar to the ECG made prior to the intervention. The postoperative elevation of transaminases in the 13 patients that underwent additional RFA and liver segment resection (COLDFIRE study) could not be solely attributed to IRE, since these additional procedures are commonly associated with such increases.
Cerebral monitoring
Prior to induction of general anaesthesia, normal cerebral activity was registered. After induction, brain activity became minimal in five (5/6) patients. During IRE, each electrical pulse was clearly registered as an artefact in all six patients (Figure 2 ). Importantly, no reactive (epileptic) activity was observed. 
Complications
Apart from the previously mentioned minor arrhythmias, no adverse events occurred during the procedures. In the postoperative period after open IRE, five complications occurred in four patients (4/13), two of which were major (re-laparotomy due to alleged persisting haemorrhage; postoperative pain). None of these complications were considered directly related to IRE but most likely to the surgical procedure.
Postprocedural complications after percutaneous IRE also occurred in five patients (5/17) after hepatic, pancreatic, renal and lesser pelvic tumour ablation (Table 2) . Of these, two were considered major complications (CTCAE grade ≥ 3).
Postoperative pain
Because all patients who underwent open IRE of the liver also had additional resection or thermal ablation, postoperative pain was unlikely to be solely related to IRE. In all but one patient, pain was well-managed with thoracic epidural analgesia.
Postprocedural pain after percutaneous IRE in the liver, pancreas, kidney and lesser pelvis was mild, with a mean maximum reported VAS score of 3 during hospital admission (range 0-9). Of these sites, pain following pancreatic IRE was the most severe with a mean maximum VAS of 4 (range 2-9) ( Table 2) . 
Discussion
IRE is a promising new technique for the local treatment of tumours ineligible for surgical resection or thermal ablation. The local application of an extremely high voltage presents several challenges in anaesthetic management that need to be anticipated (10, 11) . Results of the present study indicate that adverse effects may include cardiac arrhythmias, a transient rise in blood pressure and muscle contractions. However, these adverse effects were generally mild and easily managed. Although the size of our population precludes definitive conclusions, our results are in concordance with previous observations that IRE appears safe and feasible when a dedicated anaesthetic team takes the proper precautions.
Strong electrical currents are known to have the potential to cause arrhythmias, including ventricular tachycardia or even ventricular fibrillation (12) . Without the use of cardiac synchronization, Ball and colleagues observed brief runs of ventricular tachycardia in seven patients, which seemed to occur more frequently in close proximity to the heart (11). Of these, four were associated with a decrease in arterial blood pressure, but immediately after completion of the 10-pulse treatment cycle blood pressure and ECG rhythm returned to normal. These and other ventricular arrhythmias should be prevented by synchronizing IRE pulse delivery with the absolute refractory period of the cardiac cycle (microseconds after the R-wave) using R-wave detection (9, 10) . Since the use of synchronized pulsing, only minor arrhythmias have been reported in the literature, all of which resolved spontaneously after the procedure was aborted (7, 9, 13) . In our study, a mild and self-limiting cardiac arrhythmia was observed in two patients, one of which occurred during IRE near the left diaphragm, which is in line with previous results. According to the manufacturer, IRE is contraindicated in patients with pre-existent cardiac arrhythmias, as R-wave detection may be less reliable here, although there is no literature to support this. Since other applications such as electrical cardioversion to treat atrial fibrillation also rely on accurate R-wave detection for synchronized defibrillation shock application, this contraindication may be relative and needs to be further investigated (14) .
A transient rise in blood pressure during electroporation, usually without a simultaneous rise in heart rate, was observed in all but one patient, confirming previous observations (11) . In our study, the increase in blood pressure was effectively treated with additional propofol and remifentanil. Although the median values for the changes in blood pressure were moderate, the maximum individual response can be considered dangerous in a patient with a history of cardiovascular disease. The exact mechanism behind this rise is unclear, but stimulation of the autonomous nervous system is a likely explanation. Whether this autonomous stimulation is caused by direct stimulation or by pain perception and how it is best prevented, remains to be clarified before patients with major cardiovascular disease can be treated.
When applying high voltage pulses, neuromuscular blockade is required to avoid uncontrolled severe contractions. Ball and colleagues reported that inadequately paralyzed patients developed contractions of the entire upper body with each pulse, similar to a grand mal seizure (11) . In our study, even after confirmation of complete medicinal neuromuscular blockade (TOF=0), the electric pulses induced at least mild muscle contractions confined to the treatment area in all percutaneous procedures. These contractions were probably due to leakage current inducing a regional electromagnetic field causing direct muscle depolarization, which is not prevented by non-depolarizing neuromuscular blocking agents.
Another contraindication for IRE, and noted by the manufacturer, is epilepsy or previous seizure activity, since the electrical discharges could theoretically trigger a seizure through pulsatile brain stimulation. Electrical pulses used in electroconvulsive therapy for severe depression induce seizure activity if a frequency of >5Hz is reached, but whether IRE can induce seizures has not been firmly established (15) . Therefore, we analysed the effect of IRE on the brain in non-epileptic patients by monitoring cerebral activity with a simplified EEG.
We found an absence of background brain activity during IRE in 5/6 patients. This can be attributed to the use of propofol, which is a known suppressor of cerebral activity (16) . The high voltage seen during an electrical pulse was never followed by a reactive cerebral response in any of the patients. Indeed, the depth of anaesthesia may entirely preclude seizures. The likelihood of seizure induction by IRE is also reduced by the synchronization of pulses with the heart rhythm, meaning that they will never reach the minimum frequency of 5Hz required to provoke a seizure (17) . Based on these results and arguments, epileptic seizure risk during IRE is probably very low. If IRE were indicated in a patient with epilepsy, we suggest that use of cerebral monitoring during the procedure would allow quick seizure recognition and treatment initiation.
Postprocedural pain was previously investigated after percutaneous IRE of kidney, lung and liver. 11 Pain was well-managed with oral analgesics in almost all patients, if treatment was necessary at all. Another study showed that postprocedural pain in patients treated with either RFA or IRE for hepatocellular carcinoma was comparable, with no significant difference in analgesic requirements and without the need for epidural analgesia in any of the patients (18) . This was confirmed by our results, which showed that percutaneous IRE of the liver, kidney and lesser pelvis did not cause much discomfort. After percutaneous IRE of the pancreas a previous study found that most patients experienced (CTCAE) grade I pain (19) . Here, pancreatic ablation was associated with the greatest pain in the first 24-hours post-IRE, with maximum VAS scores up to 9, which is may be explained by the anatomic location of the pancreas near the coeliac plexus, combined with the induction of a reactive pancreatitis caused by the treatment. This pain was still effectively managed using a multimodal pain treatment consisting of acetaminophen in combination with an NSAID and opioid. The past years the relationship between opioid use and cancer recurrence has been investigated. So far, no significant differences can be identified in most studies between the post-operative use of opioids or other analgesic techniques (20) . These data are extracted from conflicting results from retrospective analyses after resection of primary cancers and not from treatment of metastases. Prospective trials are awaited to draw distinctive conclusions on the role of opioids in cancer recurrence. The relatively mild postoperative pain and limited opioid use after (percutaneous) IRE in most of our patients may be beneficial in this respect, but the numbers treated are too low to make any hard statements.
On the other hand, the relatively long duration of the procedure may have confounded the experienced postoperative pain in some patients, since continuous remifentanil infusion is associated with hyperalgesia (21).
The results in this study represent our first experience with IRE in a relatively small and heterogeneous patient group in terms of target organ and treatment approach, which permitted evaluation of IRE-related anaesthetic challenges in different organs than were reported previously. Overall, perioperative management of the patients was similar. The absence of serious cardiac arrhythmias and muscle contractions supports the assumption that they can be prevented by ECG-synchronized pulsing and profound neuromuscular blockade. Epilepsy could be regarded as a relative rather than an absolute contra-indication if IRE were considered the only local treatment option. However, our conclusions should be regarded with care because of the small sample size, which is a limitation of this study.
Future studies should focus on long-term follow-up, including long-term adverse events, local control and survival rates. From an anaesthetic perspective, it may be worthwhile to further explore the more generalized physiological consequences of IRE, since IRE is intended to induce only local effects. For example, it would be interesting to investigate the mechanism of the rise in blood pressure during IRE and whether localised muscle contractions caused by leakage currents can be prevented by using a depolarizing neuromuscular blocking agent, like succinylcholine.
In conclusion, our study suggests that adverse effects during IRE of the liver, pancreas, kidney and lesser pelvis are generally mild and easily manageable if specific perioperative precautions are taken. These include general anaesthesia with deep muscle relaxation and ECG-synchronized pulsing.
